Vargatef
Author: Dustin Phan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Vargatef (nintedanib; Boehringer Ingelheim) is a triple angiokinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), all of which play a central role in the angiogenesis pathway critical for blood vessel formation, facilitating tumor growth and metastasis. VEGF overexpression is typically associated with poor clinical outcomes, and there is evidence that PDGFR and FGFR signaling reduces the efficacy of VEGFR inhibition. Vargatef aims to block tumor growth and development through the inhibition of these angiogenic pathways.
In addition to non-small cell lung cancer, the drug is approved for idiopathic pulmonary fibrosis (branded as Ofev).
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Vargatef : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
9 Figure 75: Datamonitor Healthcare’s drug assessment summary for cemiplimab in non-small cell lung cancer
12 Figure 76: Cemiplimab sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Vargatef drug profile
7 Table 2: Vargatef pivotal trial data in non-small cell lung cancer
13 Table 3: Vargatef sales for NSCLC across the five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Namenda 
Sign up to the